Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.

Alejandro D Bendala-EstradaMariana Diaz-AlmironCarmen BuscaRafael MicanJulen CadiñanosMaría Luisa García MontesLuz Martin-CarboneroEulalia ValenciaRocío MontejanoAna Delgado-HierroJose Ignacio Bernardino

Published in: HIV medicine (2022)

In real life, switching from a triple regimen with TAF to DTG-3TC or DTG-RPV dual therapy improves the lipid profile and is an effective and well-tolerated strategy.

Keyphrases

antiretroviral therapy
stem cells
hiv infected patients
mesenchymal stem cells
smoking cessation